Logos Capital is a venture capital firm that focuses on disciplined, data-driven investments in biotechnology and healthcare. Their strategy involves utilizing a proprietary data science platform, Logos Analytics, to predict clinical trial outcomes and assess the intrinsic value of opportunities to drive groundbreaking progress in healthcare.
66% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (3 deals in the last 12 months vs 5 prior). Average disclosed round size is $112.1M (across 32 rounds with reported amounts).
Portfolio
32
Fund Size
—
Top Stage
Series B
Last 12 Mo
3
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
32 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Pinnacle Medicines | Series B | $89M | Mar 2026 |
| MMia Labs | Series A | $20M | Jan 2026 |
 Crescent Biopharma | Growth | $200M | Jun 2025 |
| VVerdiva Bio | Series A | $410M | Jan 2025 |
 35Pharma Inc. | Series C | $53M | Nov 2024 |
 Adcendo ApS | Series B | $135M | Nov 2024 |
 Elektrofi, Inc. | Series C | $112.3M | Oct 2024 |
 Attovia Therapeutics | Series B | $105M | May 2024 |
| CCompass Pathways | Unknown | $285M | Aug 2023 |
 Gracell Biotechnologies Inc. | Growth | $150M | Aug 2023 |
 Chargel | Seed | $2.5M | Apr 2023 |
 Jumba | Seed | $4.5M | Feb 2023 |
 Zeraki | Seed | $1.8M | Dec 2022 |
 Odyssey Therapeutics, Inc. | Series B | $168M | Oct 2022 |
| Jumba | Pre-Seed | $1M | Jun 2022 |
| IImaliPay | Seed | $3M | Apr 2022 |
 Bfree | Pre-Seed | $1.7M | Jan 2022 |
 Freenome | Series D | $300M | Dec 2021 |
| Odyssey Therapeutics, Inc. | Series A | $218M | Dec 2021 |
 Arbor Biotechnologies Inc | Series B | $215M | Nov 2021 |
 Obsidian Therapeutics | Series B | $115M | Sep 2021 |
 RareCyte | Series B | $24M | Sep 2021 |
 Interius BioTherapeutics | Series A | $76M | May 2021 |
| GGennao Bio | Series A | $40M | May 2021 |
 Shoreline Biosciences | Series B | $43M | Apr 2021 |
Page 1 of 2
Top Co-Investors
RA Capital Management12 shared
Janus Henderson Investors10 shared
Surveyor Capital10 shared
OrbiMed9 shared
Cormorant Asset Management6 shared
Deep Track Capital5 shared
Marshall Wace5 shared
Perceptive Advisors4 shared
Catalio Capital Management4 shared
Soleus Capital4 shared
Woodline Partners4 shared
Seedstars3 shared
Bain Capital Life Sciences3 shared
HBM Healthcare Investment3 shared
Vivo Capital3 shared
SR One3 shared
Foresite Capital3 shared
Frazier Life Sciences3 shared
Section 322 shared
Last updated: 16 April 2026